PP
EIDX

Paloma Partners’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Paloma Partners’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,359
Closed -$207K – 2670
2020
Q2 		$207K Buy
+4,359
New +$203K ﹤0.01% 1670
2019
Q4 		– Sell
-7,336
Closed -$264K – 2639
2019
Q3 		$264K Sell
7,336
-17,063
-70% -$666K 0.01% 1605
2019
Q2 		$758K Buy
+24,399
New +$661K 0.01% 831

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Paloma Partners's EIDX Position: Q3 2020 in Review

Paloma Partners sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2020, closing a stake of 4,359 shares — an estimated $207K sold.

Paloma Partners first reported a position in EIDX in Q2 2019 and held it in 3 quarters. The position peaked at $758K in Q2 2019. 91 funds tracked by Wall St. Rank hold EIDX as of Q3 2020.

  • Paloma Partners reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Paloma Partners sold 4,359 Eidos Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $207K.
  • Paloma Partners first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • Paloma Partners's Eidos Therapeutics, Inc. Common Stock position peaked at $758K in Q2 2019.
  • 91 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.